Our Management Team

Max morgan, chief executive officer

In addition to his role with Agora, Max also leads open science policy and translational initiatives for open innovation at the Structural Genomics Consortium. Prior to joining SGC, he worked as an intellectual property litigator and pharmaceutical regulatory lawyer, and more recently served as in-house counsel with Grand Challenges Canada. Max holds a B.Sc. from McGill University, a J.D. from the University of Toronto, and an LL.M. from Harvard Law School. He is a member of the Law Society of Ontario and the New York State Bar.

Peter Sampson, VP Drug Discovery & Development

Peter has over 20 years of drug discovery and development experience. He began his career as a medicinal chemist at Albany Molecular Research Inc. (Curia) and then assumed various R&D leadership roles of increasing responsibility at GlycoDesign Inc, Affinium Pharmaceuticals, the University Health Network (UHN), and Scientus Pharma. While at UHN, he led the CMC development programs for three small molecule kinase inhibitors. Most recently, Peter was the founder of IntrinsiChem Consulting Inc. where he assisted several startup biotechnology companies develop their research and business strategies. Peter holds a BSc in Chemistry from St. Mary's University and MSc and PhD degrees in Organic Chemistry from the University of Waterloo. He is the co-author of over 20 peer-reviewed publications and an inventor on over 20 patents.